

Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics

Cellanyx Diagnostics News – Announcement of New Board Member Mr. Imran Nasrullah

April 26, 2013

Cellanyx is pleased to announce the appointment of Mr. Imran Nasrullah to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Mr. Imran Nasrullah comes with tremendous business and leadership talent. Currently, he is involved with a disease foundation dedicated to curing Type 1 Diabetes, T1D First, as head of Strategic Alliances and Business Development.

Prior to T1D First, he was CBO at MassBio, one of the most influential biotechnology trade associations in the nation. While there, Mr. Nasrullah built MassBio's business & investor and economic development outreach programs to help companies raise capital and identify strategic partnering and licensing opportunities. Innovation Services constitutes a suite of services intended to stimulate: new life sciences company creation, transfer of life science assets from academia and biotechnology companies to major pharma partners, and solidifying relationships among stakeholders in the life sciences from academia to disease foundations to bio-pharmaceutical companies. Prior to the MassBio, Mr. Nasrullah worked for 10 years in the biopharmaceutical industry as directors of business development and licensing for Genzyme Corporation, Millennium Pharmaceuticals. Mr. Nasrullah started his licensing career working for Mayo Clinic and then later, the Dana Farber Cancer Institute.

Mr. Nasrullah is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.
One Marina Park Drive,
14th floor
Boston, MA, 02210
Main: 571.212.9991
Email: info@cellanyx.com